Evaluación de la actividad antiinflamatoria de una formulación intramuscular de ETORICOXIB de GINSBERG ECUADOR S.A. in vivo en ratas de laboratorio (Rattus norvergicus).

Abstract

The aim of the research was to evaluate the anti-inflammatory activity of an intramuscular formulation of ECOXIB®BLISPACK, medicine designed by the GINSBERG ECUADOR S.A pharmaceutical industry is located in the city of Quito. ECOXIB ® BLISPACK has a 1 mL prefilled syringe presentation containing 90 mg of the Etoricoxib active ingredient, a non-steroidal anti-inflammatory substance belonging to the COXIB family which selectively inhibis COX-2. Nowadays, inflammatory diseases are a very important social problem worldwide, so it is essential that the pharmaceutical industry contributes to the search for new therapy options that are effective and with the minimum risk of originating adverse effects from traditionally used drugs. For the study, 12 female rats (Wistar) between 2-3 months of age and 200-250 g of weight were used, that were distributed in 4 blocks each of them with rats of similar weights, each block was conformed by 3 experimental units to which it was induced inflames with a 1% solution of carrageenan by injection in the sub-planting region of the right leg and subsequently treated with the vehicle used in the formulation of ECOXIB ® BLISPACK (T1) as white, ECOXIB ® BLISPACK (T2) and Dynastat ® reference drug (T3) as control. The degree of inflammation of the edema was measured with a digital calibrator with a resolution of 0.1 mm at different times, 0, 1, 2.4, 8, 12, 20.24 and 27 hours; after induction of inflammation with carrageenan. In conclusion, it can be determined that both ECOXIB ® BLISPACK medicine designed by the pharmaceutical industry GINSBERG ECUADOR S. A as Dynastat ®(reference drug) are selective inhibitors of cyclooxygenase 2, belonging to the therapeutic group M01AH anti-inflammatory and anti-rheumatic (non-steroidal anti-inflammatory), showed significantly different differences in the anti-inflammatory activity.